Souhaitez-vous accéder aux communiqués récents ?

Third Quarter and First Nine Months of 2020 Revenues were $35.3 million and $101.7 million Respectively, a 7% Increase Compared to Both 2019 Periods; Company Reiterates Full-Year 2020 Total Revenue...

REHOVOT, Israel, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the...

Treatment with Kamada’s Investigational IgG Product Will Be Regulated by the Israeli Ministry of HealthInitial Order Sufficient to Treat 500 Patients Positive Interim Safety and Symptoms Improvement...

Kamada Expects to Receive $25 Million in Revenues from Sales of GLASSIA® to Takeda in 2021 which is Takeda’s Minimum Commitment for 2021 Pursuant to the Existing Supply AgreementKamada Projects...

The Phase 1/2 Open-Label, Single Arm, Multi-Center Clinical Trial is Testing Kamada’s Hyperimmune IgG Product in Hospitalized, Non-Ventilated COVID-19 Patients with PneumoniaSymptoms Improvement...

The Study of KEDRAB® (Rabies Immune Globulin [Human]) Conducted in Children was the First and Only Pediatric Study for any HRIG Available in U.S.The Study Met its Primary Objective, Which Was to...

Lilach Asher Topilsky, a Director on the Company’s Board and a Senior Partner at FIMI Opportunity Funds, Appointed Chairman Current Chairman, Leon Recanati, Remains on the Board as a Director  Ari...

Second Quarter Revenues were $33.1 million, Compared to $35.3 million in 2019, First Half 2020 Revenues were $66.4 million, up 7% from 2019 Net Income for the Second Quarter and for the First Half of...

Study Participants are Hospitalized, Non-ventilated COVID-19 Patients with Pneumonia Encouraging Neutralization Activity Observed with Virus Neutralization Assay Pre-IND Meeting with U.S. FDA to be...

REHOVOT, Israel, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), plasma-derived biopharmaceutical company, today announced that it will release financial results for the...